Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 14 | Mind Blowing Facts

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune

MarketBeat

Medtronic Bottoms, Healthy Rebound Ahead

Medtronic is on track to reverse after a major market meltdown driven by fear. The upside potential is double-digit, not including the dividend.

MarketBeat

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

GitLab’s Price Recovery Gains Traction—Time to Get On Board?

GitLab is well-positioned to drive growth long-term as its agentic push gains traction. Clients reliant on compliance and security turn to GitLab.

MarketBeat

Toro Q2 Earnings Call Highlights

Toro (NYSE:TTC) raised its full-year outlook after reporting stronger-than-expected fiscal second-quarter results, with executives pointing to broad demand across its professional and residential businesses, improving margins and benefits from its productivity initiatives. Chairman and Chief Execut

MarketBeat

Brown Forman Q4 Earnings Call Highlights

Brown Forman (NYSE:BF.A) said it finished fiscal 2026 ahead of its organic expectations, despite continued pressure from weaker discretionary spending in the U.S. and developed international markets, lower used barrel sales and the ongoing absence of American spirits from many Canadian shelves. Pre

MarketBeat

X-Energy Q1 Earnings Call Highlights

X-Energy (NASDAQ:XE) used its first earnings call as a public company to outline progress on its advanced nuclear reactor and fuel businesses, while reporting higher first-quarter revenue and grant income tied to its federal cost-share program. The company began trading on the Nasdaq on April 24 an

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

PVH Q1 Earnings Call Highlights

PVH (NYSE:PVH) said it met or exceeded its key first-quarter financial targets, helped by growth in direct-to-consumer sales and e-commerce, but lowered its full-year revenue outlook because of what executives described as the prolonged effects of the Middle East conflict on its EMEA business. Chie

MarketBeat

Columbus McKinnon Q4 Earnings Call Highlights

Columbus McKinnon (NASDAQ:CMCO) reported what management described as a “defining year” in fiscal 2026, highlighted by the completion of its Kito Crosby acquisition and the divestiture of its legacy U.S. power chain hoist and chain operations. On the company’s fourth-quarter and full-year earnings

MarketBeat

S4 Capital Touts AI Gains, Lower Debt at AGM Despite Tough Ad Market

S4 Capital (LON:SFOR) told shareowners at its annual general meeting that trading remains pressured by macroeconomic uncertainty and client caution, while management said cost controls, working capital discipline and AI-driven offerings are supporting margin improvement and debt reduction. Founder

MarketBeat

Ciena Q2 Earnings Call Highlights

Ciena (NYSE:CIEN) reported another record quarter for fiscal 2026, with management pointing to AI-related network demand from cloud providers and renewed spending by service providers as major drivers of growth. On the company’s fiscal second-quarter earnings call, President and CEO Gary Smith said

MarketBeat

Pyxus International Q4 Earnings Call Highlights

Pyxus International (OTCMKTS:PYYX) reported a sharply higher fourth quarter and record full-year adjusted EBITDA for fiscal 2026, with management pointing to strong shipment volumes, disciplined cost control and improved leverage as key outcomes from a year marked by shifting tobacco leaf supply con

MarketBeat

Ulta's Q1 Report Primes It for a Beauty of a Rebound

Ulta is setting up for a robust rebound as growth initiatives gain traction and margins outperform. Analysts forecast a 40% upside and institutions are buying.

MarketBeat

Commerzbank CEO Touts AI-Driven 2030 Plan, Calls UniCredit Offer Unattractive

Commerzbank (ETR:CBK) Chief Executive Bettina Orlopp said the German lender’s updated “Momentum 2030” strategy is built on continued revenue growth, lower costs and efficiency gains from artificial intelligence, while reiterating that the bank sees UniCredit’s current takeover offer as unattractive.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Transcontinental Q2 Earnings Call Highlights

Transcontinental (TSE:TCL.A) reported lower second-quarter revenue and slightly lower adjusted profitability from continuing operations, while management said it expects stronger results in the second half of fiscal 2026 following recent contract wins, cost reductions and the national rollout of its

MarketBeat

Canaccord Genuity Group Q4 Earnings Call Highlights

Canaccord Genuity Group (TSE:CF) reported a record fiscal 2026 revenue total and sharply higher adjusted profitability, as stronger capital markets activity and continued growth in wealth management helped offset uneven market conditions during the fourth quarter. Chairman and CEO Dan Daviau said t

MarketBeat

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia

MarketBeat

Mitie Group H2 Earnings Call Highlights

Mitie Group (LON:MTO) reported double-digit growth in revenue and operating profit for the year ended March 31, 2026, as management said the facilities management company remains on track to deliver its three-year strategic plan through FY 2027. Chief Executive Officer Phil Bentley said the company

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

CMC Markets H2 Earnings Call Highlights

CMC Markets (LON:CMCX) said it delivered a stronger financial performance in fiscal 2026 as institutional and business-to-business activity continued to scale, while management outlined plans for further investment in retail growth, product expansion and major banking partnerships. Founder and CEO

MarketBeat

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted

MarketBeat

American Public Education Unveils 2029 Growth Plan Fueled by Military and Nursing Programs

American Public Education (NASDAQ:APEI) outlined a four-year growth plan at a William Blair conference, with Chief Executive Officer Angie Selden saying the company expects revenue and adjusted earnings growth to be driven by its military-focused education business and its nursing education platform

MarketBeat

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease. Douglas Lov

MarketBeat

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China b

MarketBeat

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs

ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004. S

MarketBeat

Autodesk CFO Says MaintainX Deal Extends AI Push Across Asset Lifecycle

Autodesk (NASDAQ:ADSK) Chief Financial Officer Janesh Moorjani said the company’s recent business model changes and planned acquisition of MaintainX are intended to position the design software maker for broader participation across the full asset lifecycle, including operations and artificial intel

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.